Roy is a scientist and biotechnology entrepreneur, experienced in cancer biology, immunology, protein engineering, and clinical biomarker studies. At Pheast, Roy manages scientific processes and guides research initiatives in immuno-oncology. Previous to Pheast, he led biomarker and translational research at Forty Seven Inc., until it was acquired by Gilead Sciences in 2020. At Gilead, Roy led the biomarkers team for the anti-CD47 antibody magrolimab and the clinical-stage anti-SIRPA antibody GS-01891. Prior to Forty Seven Inc., he co-founded and led the research team at Ab Initio Biotherapeutics, an antigen-discovery company which was acquired by Ligand Pharmaceuticals in 2019. Roy is an author on multiple patents and top tier publications. He was a postdoctoral fellow at Stanford University School of Medicine in the laboratory of Dr. Irving Weissman. Roy received his Ph.D. in genetics from Columbia University and a B.A. in molecular and cell biology from UC Berkeley.